Silicon Valley says AI will cure disease, but drugmaker CEOs remains unconvinced
| Source: HN | Original article
Silicon Valley firms claim AI can cure disease, but pharmaceutical CEOs remain skeptical.
Silicon Valley’s AI optimism is meeting a skeptical reception from the pharmaceutical industry. Recent statements from leading drug‑maker CEOs underscore that, despite bold predictions from AI firms, no medicine created by artificial intelligence has yet secured U.S. Food and Drug Administration clearance. Executives argue that the fundamental challenge remains biological complexity, not computational power.
The debate was sparked by a series of high‑profile moves in the AI‑biotech space. Anthropic’s chief executive, Dario Amodei, posted on X in September that curing most human diseases within five to ten years could be achievable with AI. Since then Anthropic has acquired a stealth‑mode biotech venture and a one‑person biotech startup, while OpenAI announced the purchase of an AI‑focused drug‑discovery company in October. These investments signal Silicon Valley’s belief that large language models and generative AI can accelerate target identification, molecule design and clinical trial planning.
Pharma leaders, however, are tempering expectations. In interviews and public comments, CEOs have placed AI’s current drug‑discovery contribution below the lofty Silicon Valley narrative, noting that the absence of any FDA‑approved AI‑designed drug limits the technology’s valuation premium. Their stance echoes concerns raised earlier this month, when we reported that pharmaceutical executives remain doubtful of claims that AI could cure most diseases within a decade.
What to watch next: the rollout of Anthropic’s and OpenAI’s biotech assets, regulatory responses to AI‑generated candidates, and any pilot studies that might produce the first FDA‑cleared AI‑designed therapy. A breakthrough could shift market sentiment, but until then, the industry’s cautious tone suggests that biology, not algorithms, will dictate the pace of medical innovation.
Sources
Back to AIPULSEN